[go: up one dir, main page]

EA201892671A1 - Пегилированный свиной интерферон и способы его применения - Google Patents

Пегилированный свиной интерферон и способы его применения

Info

Publication number
EA201892671A1
EA201892671A1 EA201892671A EA201892671A EA201892671A1 EA 201892671 A1 EA201892671 A1 EA 201892671A1 EA 201892671 A EA201892671 A EA 201892671A EA 201892671 A EA201892671 A EA 201892671A EA 201892671 A1 EA201892671 A1 EA 201892671A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
pinf
pigped
pork
interferon
Prior art date
Application number
EA201892671A
Other languages
English (en)
Other versions
EA036509B1 (ru
Inventor
Питер Коннор Кэннинг
Николас Кнудсен
Лиллиан Скидмор
Original Assignee
Эланко Юэс Инк.
Амбркс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эланко Юэс Инк., Амбркс, Инк. filed Critical Эланко Юэс Инк.
Publication of EA201892671A1 publication Critical patent/EA201892671A1/ru
Publication of EA036509B1 publication Critical patent/EA036509B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

В документе раскрыты варианты свиного интерферона альфа (pINF-α), содержащие синтетическую аминокислоту в выбранных местоположениях в pINF-α и вставку одной или двух аминокислот на N-конце после удаления сигнального пептида. Варианты pINF-α могут быть дополнительно пегилированными. Также предполагаются способы получения и введения этих соединений для лечения вирусных инфекций у свиней и составы, содержащие данные варианты.
EA201892671A 2016-06-20 2017-06-16 Пегилированный свиной интерферон и способы его применения EA036509B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662352163P 2016-06-20 2016-06-20
PCT/US2017/037964 WO2017222940A1 (en) 2016-06-20 2017-06-16 Pegylated porcine interferon and methods of use thereof

Publications (2)

Publication Number Publication Date
EA201892671A1 true EA201892671A1 (ru) 2019-05-31
EA036509B1 EA036509B1 (ru) 2020-11-18

Family

ID=59258379

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201892671A EA036509B1 (ru) 2016-06-20 2017-06-16 Пегилированный свиной интерферон и способы его применения

Country Status (18)

Country Link
US (2) US10960080B2 (ru)
EP (1) EP3471755B1 (ru)
JP (2) JP7093311B2 (ru)
KR (2) KR102409470B1 (ru)
CN (2) CN117024562A (ru)
AU (2) AU2017280958A1 (ru)
BR (1) BR112018076437A2 (ru)
CA (1) CA3028683A1 (ru)
CL (1) CL2018003697A1 (ru)
DK (1) DK3471755T3 (ru)
EA (1) EA036509B1 (ru)
ES (1) ES2793773T3 (ru)
MX (1) MX391970B (ru)
NZ (1) NZ749962A (ru)
PL (1) PL3471755T3 (ru)
PT (1) PT3471755T (ru)
WO (1) WO2017222940A1 (ru)
ZA (1) ZA201808352B (ru)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3377488T3 (da) 2015-11-19 2022-10-03 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
SI3394033T1 (sl) 2015-12-22 2021-03-31 Incyte Corporation Heterociklične spojine kot imunomodulatorji
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
WO2017205464A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
IL263825B (en) 2016-06-20 2022-08-01 Incyte Corp Heterocyclic compounds as immunomodulators
EP3484866B1 (en) 2016-07-14 2022-09-07 Incyte Corporation Heterocyclic compounds as immunomodulators
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
KR102641030B1 (ko) 2016-12-22 2024-02-29 인사이트 코포레이션 Pd-l1 내재화 유도제로서의 테트라하이드로 이미다조[4,5-c]피리딘 유도체
MA47120A (fr) 2016-12-22 2021-04-28 Incyte Corp Dérivés pyridine utilisés en tant qu'immunomodulateurs
ES2934230T3 (es) 2016-12-22 2023-02-20 Incyte Corp Derivados de benzooxazol como inmunomoduladores
WO2018119236A1 (en) 2016-12-22 2018-06-28 Incyte Corporation Triazolo[1,5-a]pyridine derivatives as immunomodulators
SG11202009440WA (en) 2018-03-30 2020-10-29 Incyte Corp Heterocyclic compounds as immunomodulators
US10618916B2 (en) 2018-05-11 2020-04-14 Incyte Corporation Heterocyclic compounds as immunomodulators
AR119624A1 (es) 2019-08-09 2021-12-29 Incyte Corp Sales de un inhibidor de pd-1 / pd-l1
CN110343164A (zh) * 2019-08-22 2019-10-18 安阳工学院 一种高活性7位点突变的猪干扰素α突变体及其制备方法和应用
EP4037773A1 (en) 2019-09-30 2022-08-10 Incyte Corporation Pyrido[3,2-d]pyrimidine compounds as immunomodulators
TW202120504A (zh) 2019-11-11 2021-06-01 美商英塞特公司 Pd-1/pd-l1 抑制劑之鹽及結晶型
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
WO2022099018A1 (en) 2020-11-06 2022-05-12 Incyte Corporation Process of preparing a pd-1/pd-l1 inhibitor
TW202233616A (zh) 2020-11-06 2022-09-01 美商英塞特公司 用於製備ｐｄ－１／ｐｄ－ｌ１抑制劑以及其鹽及結晶形式之方法
CN113845599B (zh) * 2021-11-01 2023-09-19 长春萤火虫生物科技有限公司 一种重组猪干扰素融合蛋白及其应用
AR131133A1 (es) 2023-05-24 2025-02-19 Ambrx Inc INTERFERÓN l BOVINO PEGILADO Y MÉTODOS DE USO DEL MISMO

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) * 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
DE69430251T2 (de) * 1993-11-10 2002-11-07 Enzon, Inc. Verbesserte interferon-polymerkonjugate
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
JP2006213597A (ja) * 2000-07-19 2006-08-17 Pepgen Corp インターフェロン−タウを用いるｃ型肝炎ウイルスの処置のための組成物およびモニタリングの方法
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
US8906676B2 (en) 2004-02-02 2014-12-09 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
ATE529442T1 (de) * 2005-06-03 2011-11-15 Ambrx Inc Verbesserte humane interferon-moleküle und ihre verwendungen
US7695710B2 (en) * 2005-06-20 2010-04-13 Pepgen Corporation Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
TWI544930B (zh) 2007-10-01 2016-08-11 藥華醫藥股份有限公司 Ｎ端修飾之干擾素－α
UA118536C2 (uk) 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
CN104262480B (zh) * 2014-09-28 2018-03-27 重庆理工大学 重组猪长效‑α干扰素的构建和修饰方法及其冻干注射剂的制备方法

Also Published As

Publication number Publication date
EP3471755B1 (en) 2020-04-22
EA036509B1 (ru) 2020-11-18
US20190192673A1 (en) 2019-06-27
CN117024562A (zh) 2023-11-10
AU2017280958A1 (en) 2018-12-20
KR20220086700A (ko) 2022-06-23
US20210177980A1 (en) 2021-06-17
AU2021229132A1 (en) 2021-09-30
JP7441892B2 (ja) 2024-03-01
MX391970B (es) 2025-03-21
US10960080B2 (en) 2021-03-30
KR102409470B1 (ko) 2022-06-16
JP2022137063A (ja) 2022-09-21
EP3471755A1 (en) 2019-04-24
CL2018003697A1 (es) 2019-05-10
AU2021229132B2 (en) 2023-04-06
KR20190039889A (ko) 2019-04-16
KR102518451B1 (ko) 2023-04-04
BR112018076437A2 (pt) 2019-10-01
CA3028683A1 (en) 2017-12-28
NZ749962A (en) 2020-06-26
ES2793773T3 (es) 2020-11-16
DK3471755T3 (da) 2020-05-18
PT3471755T (pt) 2020-05-22
MX2018016295A (es) 2019-09-16
ZA201808352B (en) 2020-08-26
JP2019519553A (ja) 2019-07-11
WO2017222940A1 (en) 2017-12-28
JP7093311B2 (ja) 2022-06-29
CN109641034B (zh) 2023-08-15
CN109641034A (zh) 2019-04-16
PL3471755T3 (pl) 2020-10-19

Similar Documents

Publication Publication Date Title
EA201892671A1 (ru) Пегилированный свиной интерферон и способы его применения
AR122964A2 (es) Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer
MX2018000697A (es) Peptidos anti-inflamatorios y usos de los mismos.
WO2017058892A3 (en) Methods and compositions for antibody-evading virus vectors
PH12019500596B1 (en) Recombinant binding proteins and their use
EA201990071A1 (ru) Композиция пептидной вакцины
PE20190420A1 (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas
MX392683B (es) Composiciones farmaceuticas que comprenden variantes peptidicos y metodos para su uso.
EA201591702A1 (ru) Комбинация двух противовирусных препаратов для лечения гепатита c
MX392628B (es) Amortiguador de lavado de cromatografia de afinidad.
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
ES2722773T3 (es) Polipéptidos de fHbp meningocócicos modificados
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
MX387764B (es) Procedimiento de disminucion de la inmunogenicidad de proteinas y peptidos.
CL2017003097A1 (es) Composiciones y métodos para el tratamiento de la enfermedad celiaca
EA201791350A9 (ru) Радиофармацевтические комплексы
EP3766521A4 (en) PHARMACEUTICAL COMPOSITION CONTAINING AN AMINO ACID DERIVATIVE MARKED WITH 211AT, AND PROCESS FOR PRODUCING THE SAID PHARMACEUTICAL COMPOSITION
NZ756128A (en) Novel peptides and analogs for use in the treatment of oral mucositis
MX2017016227A (es) Peptidos anti-infecciosos de amplio espectro.
MX2017008994A (es) Formulacion de peptidos inhibidores mk2.
EA201590601A1 (ru) Применение pedf-производных полипептидов для лечения остеоартрита
ES2534752T3 (es) Nuevo péptido antigénico contra el cáncer y utilización del mismo
IN2015DN01371A (ru)
PH12018500468A1 (en) Fusion protein